ConductScience.org, home

Paper42017533

Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma.

Kim D and 4 others. J Vet Intern Med, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma. Papers, record 42017533. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42017533

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma.
PubMed
Journal
J Vet Intern Med
PubMed
Year
2026
PubMed
Publication types
Journal Article, Case Reports
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Dog DiseasesMajor topic
NiacinamideMajor topic
SarcomaMajor topic
Antineoplastic AgentsMajor topic
Nose NeoplasmsMajor topic
Phenylurea CompoundsMajor topic
Blood Coagulation DisordersMajor topic
Animals
Dogs
Sorafenib
Male

Source PubMed

Download CSV of topics

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
229532289Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.Angiogenesis2018https://conductscience.org/library/papers/29532289PubMed
317519900Mechanisms of adverse effects of anti-VEGF therapy for cancer.Br J Cancer2007https://conductscience.org/library/papers/17519900PubMed
430539828Bleeding risk in cancer patients treated with sorafenib: A meta-analysis of randomized controlled trials.J Cancer Res Ther2018https://conductscience.org/library/papers/30539828PubMed
536798021Comparison of a viscoelastic point-of-care coagulation monitor with thromboelastography in sick dogs with hemostatic abnormalities.Vet Clin Pathol2023https://conductscience.org/library/papers/36798021PubMed
637532540Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma.J Vet Med Sci2023https://conductscience.org/library/papers/37532540PubMed
717215530Sorafenib in advanced clear-cell renal-cell carcinoma.N Engl J Med2007https://conductscience.org/library/papers/17215530PubMed
839496212Point-of-care viscoelastic coagulation monitoring device shows promise for informing resuscitation strategies in a canine hemorrhagic shock model.Am J Vet Res2025https://conductscience.org/library/papers/39496212PubMed
915466206BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res2004https://conductscience.org/library/papers/15466206PubMed
1039126006Immunohistochemistry Screening of Different Tyrosine Kinase Receptors in Canine Solid Tumors-Part I: Proposal of a Receptor Panel to Predict Therapies.Int J Mol Sci2024https://conductscience.org/library/papers/39126006PubMed
1132443457Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs.Cancers (Basel)2020https://conductscience.org/library/papers/32443457PubMed
1233368568Establishment of normal reference intervals in dogs using a viscoelastic point-of-care coagulation monitor and its comparison with thromboelastography.Vet Clin Pathol2020https://conductscience.org/library/papers/33368568PubMed
1324768112Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.Lancet2014https://conductscience.org/library/papers/24768112PubMed
1430050861Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer.Vet Med (Auckl)2017https://conductscience.org/library/papers/30050861PubMed
1519581909Adverse effects of anticancer agents that target the VEGF pathway.Nat Rev Clin Oncol2009https://conductscience.org/library/papers/19581909PubMed

Download CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42017533

GET https://conductscience.org/api/papers/v1/42017533/authors